Apogee Therapeutics, Inc. — Director's Dealing 2023

Dec 21, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Apogee Therapeutics, Inc. (APGE)
CIK: 0001974640
Period of Report: 2023-12-18

Reporting Person: Henderson Jane (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-12-18	Stock Option (Right to Buy)	$22.86	A	175345	Acquired	2033-12-18	Common Stock (175345)	Direct

Footnotes

F1: This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments over a four-year period from the date of grant, subject to the Reporting Person's continued service to the Issuer.